Myomo, Inc. (MYO) Earnings Call Transcript
November 9, 2026
Earnings Call Speaker Segments
Thanks, operator, and good afternoon to all of you. I'm Vivian Cervantes, calling in from Alliance Advisors IR. It's my pleasure to welcome you to the conference call covering Myomo's financial results for the third quarter of 2026. Joining us on the line today are Paul Gudonis, Myomo's Chief Executive Officer, and Dave Henry, our Chief Financial Officer. Prior to starting, I want to remind listeners that anything management says on this call that isn't a historical fact constitutes a forward-looking statement. Typically, terms such as "anticipate," "believe," "estimate," "expect," "intend," "guidance," "outlook," "confidence," "target," "project," and similar expressions signal those forward-looking statements. Such statements don't guarantee future performance, and they may involve and are subject to risks, uncertainties, and other factors that could affect Myomo's business, financial condition, and operating results. Myomo's filings with the SEC discuss these risks, uncertainties, and other factors. What actually happens and the results we achieve could differ materially from what these forward-looking statements express or imply. Also, unless the law requires it, Myomo assumes no obligation to revise or update any forward-looking statement to reflect events or circumstances occurring after today's call date, November 9th, 2026. Now it's my pleasure to hand things over to Myomo CEO Paul Gudonis. Paul, please go ahead.
Thanks, Vivian, and good afternoon, everyone. Thank you all for being with us today. Myomo's mission is to assist individuals dealing with chronic paralysis of the arm and hand in regaining independence and function through our powered arm braces. During the third quarter, we advanced in serving more of these patients while enhancing the financial performance of our business. Revenue hit a quarterly record of $12.3 million, a 22% increase from a year ago. Gross margin climbed to 71.3%, and we achieved roughly break-even adjusted EBITDA. The results we're reporting reflect continued movement on the four success pillars we discussed last call: building recurring patient referral streams, expanding payer coverage, demonstrating operating leverage, and investing in product development and clinical research. I'll walk through what we achieved on each. Pillar one is about increasing revenue from recurring patient sources. During the third quarter, patients referred to us by rehab hospitals and stroke clinics, by orthotics and prosthetics partners, and by the VA made up 54% of revenue, compared with 33% in the same period last year. That speaks to how well MyoConnect is working — the program is now in year two. To date, more than 500 rehabilitation facilities and therapy centers have had healthcare professionals send us potential MyoPro patients. That represents an increase of over 200 locations during the last quarter. With that milestone, we now have a broader set of relationships through which patients can learn about the device while receiving care, and it lets us build a more durable business over time rather than relying only on direct-to-patient marketing. An increasing number of physicians and therapists are recommending a MyoPro for their patients, and as they see the benefits the MyoPro provides to those patients, we expect more referrals per facility; we are already seeing this same-store sales growth. Over 30% of the referrals we received lately originated from sites already working with us — therapists and physicians familiar with our company, our product line, the published clinical research, and the positive results their patients have achieved with MyoPro. That growth in referring locations helped drive the quarter's record order volume, which reached 258 orders in the third quarter. Expanding market access so that more qualified patients can obtain a MyoPro is the second of our success pillars. In the quarter, we have either signed agreements or are working to finalize them with payers representing an additional 35 million covered lives. Where contracts are already finalized with payers, we're working to launch as an in-network provider, and those agreements cover both the payers' Medicare Advantage and commercial plans. We've also moved forward with state Medicaid agencies, and we're now enrolled in seven states, including Pennsylvania, Michigan, and Wisconsin. Additional state Medicaid plans are lined up; this will benefit patients holding Medicaid in those states, subject to each plan's medical coverage policies, along with letting us collect secondary insurance payments for our Medicare patients who may live in those states. We intend to keep signing additional agreements like these, since our history shows a greater pre-authorization rate for the MyoPro when we operate as an in-network provider. Generating operating leverage is the third of our success pillars. We aim to increase revenues at a pace at least double that of operating expenses. That objective was met once more in the third quarter, with revenue up 22% year-over-year while operating expenses rose only 6%. Gross margin also gained 750 basis points in the third quarter versus the prior year. We remain on the road toward profitability and sustainable positive cash flow, pursuing further cost reductions — for example, bringing in-house the 3D printing of the custom-fabricated shells for each MyoPro, which is expected to go live by the end of this year. Our efficiency work in other functional areas is delivering financial results as well, with overall volumes higher even though our head count has declined over the past two years. Continued progress in product development and clinical research is our fourth success pillar. The randomized controlled trial at the University of Utah keeps advancing steadily, with 35 of the planned 50 subjects enrolled now, compared with 25 when we held our second quarter call. Additionally, we continued work on both the MyoPro 3 and the hand-only device aimed at the German market. This effort is part of a broader, longer-term push to expand the evidence base and the range of applications for our wearable robotics platform. As milestones are reached, we'll provide further updates. Overall, the quarter showed how execution across our four pillars of success reinforces one another. More referral partnerships and payer access contribute to record orders and revenue. Higher volume combined with reduced costs supports an improved gross margin and stronger operating results. By investing in the clinical, commercial, and product capabilities needed to reach more patients, we are extending our market-leading position. Last month we shared that Katie McClure has come aboard Myomo as Chief Commercial Officer, a move aimed at helping us keep expanding our commercial activities. Her background includes a strong track record of revenue growth, forming solid referral partnerships, and overseeing a sales and field clinical team during her tenure at Inspire Medical, a fast-growing company, along with other medical device firms. I'm pleased that she's bringing this expertise to Myomo as we pursue our strategy to better serve the substantial, unmet need for chronic arm paralysis across the country. With that summary, I'll turn things over to Dave Henry, who will walk through our financial results in more detail.
Thanks, Paul, and good afternoon to all of you. Revenue in the third quarter of 2026 reached a record $12.3 million, which was 22% higher than the same period a year earlier. Growth came from two places: a rise in average selling price, or ASP, and a greater count of revenue units. ASP came in at roughly $55,500 for the quarter, an increase of about 2% over the prior year, and we booked revenue on a record 222 MyoPro units — 19% more than in the third quarter of 2025. On payer mix, Medicare Part B patients accounted for 54% of third quarter revenue and also 54% of prior-year period revenue. Medicare Advantage plans made up 17% of third quarter revenue, versus 18% in the second quarter of 2025. Our shift toward recurring patient sources kept gaining momentum through the quarter. Recurring patient sources accounted for 54% of third quarter revenue, compared with 33% in the prior-year quarter. Inside those recurring channels, direct billing referrals through our MyoConnect program produced 27% of total revenue, up from 23% in the second quarter and 20% in the first quarter of 2026; results from our other recurring channels remain strong, with international revenue at 17% of revenue and US O&P revenue at 8% of revenue. VA patients made up 2% of revenue in the third quarter. On our metrics, we booked a record 258 MyoPro orders in the quarter, a 13% increase year-over-year; we added 600 patients to the pipeline during the quarter, a decline relative to the second quarter of 2026. MyoConnect referrals accounted for 18% of pipeline adds in the third quarter. Third quarter MyoConnect pipeline adds were affected by third quarter seasonality from summer vacations among referring sources, along with temporary internal staffing constraints. Those staffing constraints have been alleviated as we enter the fourth quarter. Our direct-to-patient advertising spending rose 2% year-over-year. Advertising-driven pipeline adds in the quarter were hurt by an inefficiency in our lead generation, which yielded fewer workable leads and a lower conversion rate among those generated in the quarter. We keep testing new methodologies for patient targeting so we can maximize spend effectiveness and optimize customer acquisition cost. With the MyoConnect resource constraints just mentioned alleviated and improvements in direct-to-patient lead generation implemented, we generated roughly 30% more direct billing pipeline adds in October than the per-month average in the third quarter. We closed the quarter with a backlog of 217 patients, down modestly from the second quarter, as operational efficiency converted the quarter's record orders into a record number of revenue units. On our financial results, gross margin in the second quarter was 71.3%, up from 63.8% in the prior-year quarter. The gain was driven mainly by the higher ASP, material cost reductions, and the spreading of fixed costs across a higher number of revenue units, partly offset by somewhat higher clinical costs reclassified to cost of goods sold. Operating expenses were $10.5 million, an increase of 6% compared with the third quarter of 2025. During the quarter, higher general and administrative costs and R&D spending were offset by reduced sales, clinical, and marketing expenditures. Our operating loss showed substantial improvement, coming in at $1.7 million versus $3.5 million in the same quarter last year. In the third quarter we reached adjusted EBITDA break-even, compared with a $2.7 million loss a year earlier. Our sharp focus is on operating leverage and keeping cash burn to a minimum while we invest prudently in MyoConnect. Keep in mind that part of the adjusted EBITDA improvement stems from increased stock-based compensation expense, since certain employee incentive payments were made in stock during the third quarter as part of our cash management initiatives. We anticipate stock-based compensation expense will revert to its normal run rate in the fourth quarter. Beneath the operating loss line, second quarter results reflect a non-cash charge of roughly $1.8 million tied to a mark-to-market adjustment in the valuation of our derivative liabilities, along with cash and non-cash interest expense related to the Avenue Capital term loan. Taking that non-cash charge into account, the net loss for the third quarter came to $4.2 million, or $0.10 per share, versus $3.7 million, or $0.09 per share, in the third quarter of 2025. Moving on to the balance sheet and cash flow: as of September 30th, 2026, cash, cash equivalents, and short-term investments came to $11.9 million. Operating activities used $1.3 million in cash during the second quarter, versus $1.8 million used in the third quarter of 2025. Cash burn — the quarter's change in cash — amounted to $1.5 million, better than the $2.2 million seen in the second quarter. I'll wrap up with our outlook. During the last quarter, we lifted our full-year guidance to a range of $45 million to $47 million. Today we are tightening that guidance to $46 million to $47 million, the top portion of the earlier range. We anticipate that the favorable impact of manufacturing cost reduction initiatives will produce a modest sequential rise in gross margin during the fourth quarter. One-time costs tied to the transition of our Chief Commercial Officer, together with higher head count supporting our MyoConnect program, are expected to bring a modest sequential increase in operating expenses in the fourth quarter. Even with that expected increase, we are holding to our previously communicated operating leverage objective of limiting operating expense growth for all of 2026 to half the rate of 2026 revenue growth. We still expect total cash burn in the second half of the year to come in under $2 million, or under $500,000 in the fourth quarter. On the whole, we're pleased to be positioned to meet or beat our financial and operating objectives for 2026, and we look forward to continued execution in 2027. With that financial overview, I'll hand the call back to Paul.
Thanks, Dave. So to recap, across the last year we carried out all 4 of the pillars behind our success in growing Myomo's volume and revenues, and at the same time we made gains on important financial measures — gross margin, adjusted EBITDA, and cash usage. In September I was at the American Orthotic and Prosthetic Association National Conference, where we sat down with new and current O&P partners to build deeper ties within this channel, so they can add another product to the treatment plans they offer stroke patients. As an illustration of these relationships in action, a national provider recently introduced our MyoConnect clinicians to one of its hospital referral sources, and that produced several patients added to their candidate pipeline plus delivery of their first MyoPro to a patient who now can use that arm and hand again after years without that ability. We're eager to repeat such wins in our US and German markets, since a very large opportunity lies ahead of us to better the lives of many people through our proprietary technology; we've made Myomo the market leader, with more than 4,000 devices supplied to patients living with paralysis, and even so that represents only roughly 1% penetration of the addressable market. More than 3 million people in the US live with chronic arm paralysis, and there are another 250,000 cases arising from the 800,000 strokes occurring each year in the US; we've already built the foundation for carrying out our strategy of ongoing market penetration and revenue growth by bringing on extra field clinical staff throughout the US and Germany to cultivate more referral relationships with the physicians and therapists who treat these patients. This shift in how we go to market will produce a growing, durable business that serves this patient population in the years ahead. Now Dave and I are ready for your questions. Operator? While we wait for the first question, I want to note that next week we'll take part in the Craig-Hallum 17th Annual Alpha Select Conference in New York on November 17th. Dave and I, together with our new Chief Commercial Officer, Katie McClure, will be there in person at this conference and available for one-on-one meetings. Hey, operator, let's take the first question whenever you're ready.
Good afternoon, and thank you for taking the questions. I have a couple, maybe starting first with pipeline adds. We haven't seen this kind of seasonality in Q3 before. Do you expect that to continue going forward, now that MyoConnect is a bigger piece of the pipeline strategy? Then second, the guidance implies most of the change was here in Q3. I'd appreciate your thoughts on October for pipeline activity, now that MyoConnect brings a higher percentage of adds that are filled. Is there some potential conservatism in Q4, or how should we think about some of the positive indicators you gave around October?
On pipeline adds, there were a couple of things. The seasonality I mentioned was more around MyoConnect and trying to schedule screening days and things like that at these referring locations — we just found it was a bit harder to do so during the summer months. The other part on the advertising side, I did mention there were inefficiencies in the quarter; that contributed to the 600 pipeline adds. What I mentioned was that the combination of the staffing constraints we also had on the MyoConnect side during the third quarter, combined with what we think is fixing some of these inefficiencies on the DTC side, resulted in the 30% increase in pipeline adds in October. Remember though that advertising is seasonally lower in the fourth quarter compared to third; it's something we always do. Keep that in mind as you look at any projections for pipeline adds in third in fourth quarter. In terms of the conservatism or in our forecast, I would just say that we try to give guidance that we believe is achievable.
Got it. Perhaps focusing just on the commercial side of things. With Katie now leading that area, what changes should we anticipate when it comes to commercial strategy and go-to-market?
Thanks, Chase. She has now been with us for a month and has spent time out in the field with our team. She is examining our organizational setup and where we should be adding staff; over the last 30 days we have already brought on several additional clinicians in the field, since we see this enormous opportunity. She is reviewing how we should organize, where more clinical staff ought to be placed, compensation plans, and similar matters. Stay tuned. It has only been 30 days for her here, yet she comes with a wealth of experience from an outstanding record of growing Inspire Medical's business across the 8 years she spent there.
Got it. Just one thing from me — I know you're definitely not providing guidance here, but I'd appreciate hearing some early thinking on '27. I suppose, do you feel the range you've guided for 2026 on revenue growth can carry over into 2027, and is that a reasonable way for us to frame possible growth? And second, for '27, are you expecting the same leverage goal you gave for 2026, with revenue increasing at twice the rate of operating expenses? Thanks.
Sure. I guess I'll address the second question first. Right now we're in the middle of our planning process for 2027, so I'll hold off answering on the leverage target until those plans are finalized; then regarding revenue, we're making this transition and we're in the middle of it now, and I think we did a pretty solid job in 2026 working to shift more of our revenues so they come from recurring patient sources. We intend to keep building on that in 2027 and to carry forward the progress we've achieved. Although I'm not offering any revenue guidance today, we're focused on attempting to grow revenue as fast as we're able to grow it, while simultaneously ensuring we maximize that operating leverage and keep the burn to a minimum.
Got it. Thanks, guys.
Good afternoon, and thanks for taking my question. First, out of those 500-plus MyoConnect locations, how should we think about what share is actually sending orders your way? Should we view it through the 80/20 lens, where the top 20% produce 80% of the referrals? And if that's how it works, what do you plan to do to maybe close that gap between the strongest performers and the ones further down?
Thanks, Jeremy. This MyoConnect program is really only a little more than a year old at this point. For most of these referring facilities, we came in, sat down with the physicians and the therapists, ran the in-services and education, and got an initial referral. Usually the way it goes is they refer one patient to us. They want to be sure that patient is medically qualified and that the insurance will cover the device. Then once they get the device, these referring facilities will treat those patients. There's a 12-week Myomo therapy training protocol. After that, as they witness these good outcomes, they'll refer a second and a third patient. We're seeing that happen. The ones that first came on a year ago are already beginning to refer the second, third, or more patients. Many of them, as I mentioned, we had over 200 new ones in this third quarter, typically have only done their first patient so far. I expect that over time, we'll see the same-store sales growth as they observe the good outcomes from their referred patients. Roughly 30% of the referrals in the quarter came from these referring facilities that already had experience with MyoPro.
Understood. Do you observe an improved conversion rate — a greater rate of conversion from those MyoConnect referrals than what you've typically seen from DTC, say?
Yeah, on a couple of fronts. To begin with, we're seeing that medically these patients are better qualified, since with direct-to-consumer marketing anyone at all might see an ad and then reach out to us, after which we evaluate that patient; and because our clinicians do such a strong job of clarifying who is a suitable MyoPro candidate according to their inclusion criteria, we're finding that a larger share of these patient referrals in fact make it into the pipeline. After that, since we lay out which payers are common in a given region—be it Medicare Part B, particular Blue Cross plans, or other insurers that cover the device—we also observe an improved authorization rate. In my view, the calibre of the pipeline generated by these referrals is considerably stronger, both in terms of medical qualification and with respect to reimbursement qualification.
Got it. Great. So just this final question from our side. You mentioned the DTC was facing some headwinds during this quarter. I know other companies have told us it's tied to Google — the AI Overviews really blocking the click-throughs you'd normally receive. How should we think about that, what were the problems, and then what actions did you take to fix them? Thanks.
I don't think so. When we think about social media and lead generation, most of it comes from Meta. I'm not sure whether Google and whatever issues they had — I'm actually not aware of them — really had much of an impact with respect to our pipeline adds in third quarter.
Right. Got it. Fine. I’ll rejoin the queue then. Thanks.
Thanks, and good afternoon. To begin, Dave, did you provide a cumulative reimbursement pipeline figure for us?
I didn’t, but at the close of the third quarter it stands at slightly more than 1,400.
Great. When we look at the metrics and, you know, the model that most people used to arrive at product placements, the top of the funnel was always pipeline adds — that was always the key figure for gauging growth. Now that over 50% comes from recurring patient sources, I guess, first of all, do all of those people make it through the top of the funnel? And second, given that half the patients are coming from recurring sources, should we be looking at this a little differently now?
On pipeline adds, we still collect information for O&P providers to the degree that they give it to us. We also collect it from our operations in Germany, and obviously as well as direct-to-patient marketing. Now, speaking specifically of direct billing, whether a patient arrives via a referral or through advertising, we still track pipeline adds. For your modeling, I think I'd say pipeline adds remains the key metric to look at. And I'll say — and I think Paul just brought this up in response to an earlier question — that as pipeline adds become more weighted toward MyoConnect in the future, we would expect those pipeline adds to convert into revenue better than direct-to-patient. I think I gave a stat, I believe last quarter, which still holds true, that roughly 10 times MyoConnect pipeline adds turn into revenue at a rate 10 times better than direct-to-patient advertising. I still think pipeline adds is still a good metric to model off of going forward.
So as the hit rate climbs since the quality of the adds is better, do you figure the total pipeline adds are still going to drift upward? Could they drift up more slowly given that the hit rate is higher? I'm just trying to get a sense, because it seemed like we were headed toward 800, steadily in the 800s, and maybe eventually reaching four digits. Perhaps that takes longer now if the hit rate is higher, which isn't a bad thing. I just wanted your view on how we should think about that top of the funnel.
Obviously, we'd like to see that top of the funnel be as high as we possibly can, but that hit rate, as you say, will have an effect because, when it comes to growing revenue, the quality of those pipeline adds matters more than the sheer volume of them, since that's ultimately what will drive revenue going forward. Put another way, 800 pipeline adds yesterday isn't the same as 800 pipeline adds in the future going forward, because of this transition we're making toward recurring patient sources.
Is there anything different you're seeing on the Medicare side in Q4 compared with Q3, or even Q3 compared with Q2? How is that developing, or should we perhaps focus more on the start of next year for where some changes might show up?
We're still being reimbursed under our HCPCS code for Medicare Part B patients. With the right medical documentation, every one of those patients is receiving reimbursement for their device. In cases where we're in-network under a payer's contract, those agreements frequently cover Medicare Advantage or commercial plans, and our authorization rate is higher in those situations than when we're an out-of-network provider. That's the reason we keep investing in securing additional payer contracts, since that approach does bring us more Medicare Advantage authorizations.
Great. This will be my last question. I know earlier questions touched on how you see revenue growth in 2027. Maybe to dig into it a bit more, what's your view of the pricing environment from here? Should we look for incremental improvement, or possibly, as new models come out, even bigger pricing gains? I just wanted to hear your perspective on that.
Thanks, Scott. Pricing in the US is mostly determined by what CMS allows. The flagship MyoPro G is at $68,800 now. Medicare has raised prices roughly 2%, 2.5% over the last couple of years, tracking cost-of-living increases. Whether that continues, I can't say, but CMS really sets that pricing, and it then serves as the benchmark for all the commercial contracts we sign. Our O&P pricing is closer to wholesale, since they handle all the clinical work and the reimbursement work involved in getting the device to patients; in Germany, pricing is again set by the payers, the statutory health insurers like TK and others, who essentially take our pricing and work with the O&P that actually gets reimbursed for the device. We have no plans to change that. It really depends on what CMS does.
Excellent, and thanks for fielding our questions.
Happy to help.
Hi there, good afternoon, Paul and Dave, and congratulations on a fantastic quarter. I've got a few questions. First, regarding gross margin, we can see it's risen considerably compared with a year ago, though it slipped somewhat from the prior quarter. I'm curious about what's driving that figure up and what's pulling it down. And when it comes to items such as the 3D printing relocation and the hand-only device in Germany, taking those into account, how should we expect margins to trend from here?
Appreciate the question. Breaking down that 750 basis point year-over-year gross margin gain: roughly 90 points, 90 basis points, came from the 2% year-over-year ASP increase; around 190 basis points came from material cost reductions we've implemented, and more are still on the way, for instance, as you pointed out, the 3D printing; the remainder was mostly from higher volume and fixed costs being spread across that greater volume. Paul noted that we've kept head count constrained as much as we can, and that is flowing through as gains on the gross margin line. Then, looking ahead at gross margins, I'd still suggest a low 70s gross margin is what you ought to model. There will be gradual improvements. As I said, we anticipate fourth quarter gross margin will be somewhat higher as some of these improvements kick in. Then, as I mentioned, I'd stay in that low 70s territory as you head into 2027.
Understood; that's really useful. My final question concerns reimbursement. As you said, authorization rates tend to improve once you're in-network and approved by those payers. I was wondering whether you could give some detail on how much authorization rates rise once you're in-network? And roughly how many payers do you anticipate adding over the coming year in terms of new coverage?
Rather than going plan by plan, I'd say some payers show a far better authorization rate. They aren't at 100% the way we see with Medicare Part B patients, but they're definitely better than when no contract exists, and that's the reason we'll keep securing more of these contracts; then in cases where we're enrolled in state Medicaid plans, those plans frequently cover the secondary copay for Medicare Part B patients. That assists in lifting our ASP by gathering that secondary insurance payment from the state Medicaid plan for particular patients.
Understood—that covers everything on my end, and I appreciate your time in answering my questions.
Wonderful. Thank you, Sean. It was nice to see you at the H.C. Wainwright conference in September.
Nice work on the quarter. I've got a question about Germany. You've performed really well there. Has the moment arrived to widen your sights past Germany to other EU nations? Thanks.
Thank you, Ed. Things are going great in Germany — record revenues for another year, growth versus the prior year, that kind of thing. We'll keep pushing harder in Germany. It's a large market. As with the US, penetration there remains quite small to date. We've brought on a few additional clinical people and business development people already to sustain the growth of that sales force. If I consider where the best return on a euro comes from, should I put money into trying to launch in new markets, or simply do more in Germany, since that turns into revenue far faster? At present, despite the fact that other market opportunities clearly exist throughout Europe, we are doubling down and simply doing more in Germany. The new hand product being created for Germany, launching in 2027, will open the market up even more, because at the moment some patients don't medically qualify for the MyoPro — they might have elbow movement yet lack hand function; that product will meet a need and widen the market potential further for us in Germany, and after that we'll bring it over here to the US.
Excellent, I appreciate your responses to my questions, and best of luck to you all. Thanks very much.
Wonderful. Thanks to you, Edward.
Thanks, operator, and I appreciate everyone being with us today and for the questions you raised. We’re looking forward to seeing you and hearing from you over the next few months. Have a good evening, and thanks once more. Goodbye.
That brings this conference to a close. We appreciate your joining today's presentation. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Myomo, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Myomo, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.